Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 8/2005

01-08-2005 | Original Article

Lysophosphatidic acid stimulates fas ligand microvesicle release from ovarian cancer cells

Authors: Yuru Meng, Shijun Kang, David A. Fishman

Published in: Cancer Immunology, Immunotherapy | Issue 8/2005

Login to get access

Abstract

Previous reports support that lysophosphatidic acid (LPA) upregulates Fas ligand (FasL) cell surface presentation on the ovarian cancer cells. In this study, we aim to investigate soluble FasL (sFasL) secretion associated with the small membrane microvesicles upon LPA stimulation, and to analyze the roles of cytoskeletal reorganization in FasL transport induced by LPA. Ovarian cancer cells were stimulated with LPA and spent media were harvested, concentrated, and ultracentrifugated to collect the supernatant and pellet. Western blot suggested that sFasL released from ovarian cancer cells were the mature form, and these sFasL are released with the small membrane microvesicles. Flow cytometry showed that the majority of microvesicles secreted contained FasL on their membrane, and these small membrane microvesicles are bioactive against activated human T lymphocytes. The microtubule-disrupting reagent nocodazole, not the actin-filament-disrupting reagent cytochalasin D pretreatment blocked FasL-expressing small membrane microvesicle release stimulated by LPA, suggesting that microtubules play an essential role in FasL microvesicle transport and exocytosis. LPA may promote ovarian cancer metastasis by counterattacking peritoneal cavity anti-tumor immunity.
Literature
1.
Linkermann A, Qian J, Janssen O (2003) Slowly getting a clue on CD95 ligand biology. Biochem Pharmacol 66:1417–1426
2.
Abrahams VM, Straszewski SL, Kamsteeg M, Hanczaruk B, Schwartz PE, Rutherford TJ, Mor G (2003) Epithelial ovarian cancer cells secrete functional Fas ligand. Cancer Res 63:5573–5581
3.
Martinez-Lorenzo MJ, Anel A, Alava MA, Pineiro A, Naval J, Lasierra P, Larrad L (2004) The human melanoma cell line MelJuSo secretes bioactive FasL and APO2L/TRAIL on the surface of microvesicles. Possible contribution to tumor counterattack. Exp Cell Res 295:315–329
4.
Andreola G, Rivoltini L, Castelli C, Huber V, Perego P, Deho P, Squarcina P, Accornero P, Lozupone F, Lugini L, Stringaro A, Molinari A, Arancia G, Gentile M, Parmiani G, Fais S (2002) Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med 195:1303–1316
5.
Baram D, Linial M, Mekori YA, Sagi-Eisenberg R (1998) Ca2+-dependent exocytosis in mast cells is stimulated by the Ca2+ sensor, synaptotagmin I. J Immunol 161:5120–5123
6.
Baram D, Mekori YA, Sagi-Eisenberg R (2001) Synaptotagmin regulates mast cell functions. Immunol Rev 179:25–34
7.
Hibi T, Hirashima N, Nakanishi M (2000) Rat basophilic leukemia cells express syntaxin-3 and VAMP-7 in granule membranes. Biochem Biophys Res Commun 271:36–41
8.
Wu X, Bowers B, Rao K, Wei Q, Hammer JA III (1998) Visualization of melanosome dynamics within wild-type and dilute melanocytes suggests a paradigm for myosin V function in vivo. J Cell Biol 143:1899–918
9.
Fletcher LM, Welsh GI, Oatey PB, Tavare JM (2000) Role for the microtubule cytoskeleton in GLUT4 vesicle trafficking and in the regulation of insulin-stimulated glucose uptake. Biochem J 352(Pt 2):267–276
10.
Smith AJ, Pfeiffer JR, Zhang J, Martinez AM, Griffiths GM, Wilson BS (2003) Microtubule-dependent transport of secretory vesicles in RBL-2H3 cells. Traffic 4:302–312
11.
Taunton J, Rowning BA, Coughlin ML, Wu M, Moon RT, Mitchison TJ, Larabell CA (2000) Actin-dependent propulsion of endosomes and lysosomes by recruitment of N-WASP. J Cell Biol 148:519–530
12.
Tomishige M, Sako Y, Kusumi A (1998) Regulation mechanism of the lateral diffusion of band 3 in erythrocyte membranes by the membrane skeleton. J Cell Biol 142:989–1000
13.
Zhang Q, Magnusson MK, Mosher DF (1997) Lysophosphatidic acid and microtubule-destabilizing agents stimulate fibronectin matrix assembly through Rho-dependent actin stress fiber formation and cell contraction. Mol Biol Cell 8:1415–1425
14.
Cook TA, Nagasaki T, Gundersen GG (1998) Rho guanosine triphosphatase mediates the selective stabilization of microtubules induced by lysophosphatidic acid. J Cell Biol 141:175–185
15.
Chrzanowska-Wodnicka M, Burridge K (1994) Tyrosine phosphorylation is involved in reorganization of the actin cytoskeleton in response to serum or LPA stimulation. J Cell Sci 107(Pt 12):3643–3654
16.
Seufferlein T, Rozengurt E (1994) Lysophosphatidic acid stimulates tyrosine phosphorylation of focal adhesion kinase, paxillin, and p130. Signaling pathways and cross-talk with platelet-derived growth factor. J Biol Chem 269:9345–9351
17.
Takuwa Y, Takuwa N, Sugimoto N (2002) The Edg family G protein-coupled receptors for lysophospholipids: their signaling properties and biological activities. J Biochem (Tokyo) 131:767–771
18.
Meng Y, Graves LA, Do TV, So J, Fishman DA (2004) Up-regulation of FasL by LPA on ovarian cancer cell surface leads to apoptosis of activated lymphocytes. Gynecologic Oncology (in press)
19.
Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A, Tschopp J (1998) Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 187:1205–1213
20.
Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S (1997) Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med 186:2045–2050
21.
Tanaka M, Itai T, Adachi M, Nagata S (1998) Downregulation of Fas ligand by shedding. Nat Med 4:31–36
22.
Blott EJ, Griffiths GM (2002) Secretory lysosomes. Nat Rev Mol Cell Biol 3:122–131
23.
Ridley AJ, Hall A (1992) The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 70:389–399CrossRefPubMed
24.
Barry ST, Critchley DR (1994) The RhoA-dependent assembly of focal adhesions in Swiss 3T3 cells is associated with increased tyrosine phosphorylation and the recruitment of both pp125FAK and protein kinase C-delta to focal adhesions. J Cell Sci 107(Pt 7):2033–2045
25.
Martinez-Lorenzo MJ, Anel A, Gamen S, Monle nI, Lasierra P, Larrad L, Pineiro A, Alava MA, Naval J (1999) Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles. J Immunol 163:1274–1281
26.
Monleon I, Martinez-Lorenzo MJ, Monteagudo L, Lasierra P, Taules M, Iturralde M, Pineiro A, Larrad L, Alava MA, Naval J, Anel A (2001) Differential secretion of Fas ligand- or APO2 ligand/TNF-related apoptosis-inducing ligand-carrying microvesicles during activation-induced death of human T cells. J Immunol 167:6736–6744
27.
Golstein P (2000) Signal transduction. FasL binds preassembled Fas. Science 288:2328–2329
28.
Holler N, Tardivel A, Kovacsovics-Bankowski M, Hertig S, Gaide O, Martinon F, Tinel A, Deperthes D, Calderara S, Schulthess T, Engel J, Schneider P, Tschopp J (2003) Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol 23:1428–1440
29.
Marks MS, Seabra MC (2001) The melanosome: membrane dynamics in black and white. Nat Rev Mol Cell Biol 2:738–748
30.
Frigeri L, Apgar JR (1999) The role of actin microfilaments in the down-regulation of the degranulation response in RBL-2H3 mast cells. J Immunol 162:2243–2250
31.
Holowka D, Sheets ED, Baird B (2000) Interactions between Fc(epsilon)RI and lipid raft components are regulated by the actin cytoskeleton. J Cell Sci 113(Pt 6):1009–1019
32.
Davis BM, Cabot JB (1984) Substance P-containing pathways to avian sympathetic preganglionic neurons: evidence for major spinal–spinal circuitry. J Neurosci 4:2145–2159
33.
Seagrave J, Oliver JM (1990) Antigen-dependent transition of IgE to a detergent-insoluble form is associated with reduced IgE receptor-dependent secretion from RBL-2H3 mast cells. J Cell Physiol 144:128–136
34.
Stinchcombe JC, Bossi G, Booth S, Griffiths GM (2001) The immunological synapse of CTL contains a secretory domain and membrane bridges. Immunity 15:751–761
35.
Bossi G, Griffiths GM (1999) Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells. Nat Med 5:90–96
36.
Goetzl EJ, An S (1998) Diversity of cellular receptors and functions for the lysophospholipid growth factors lysophosphatidic acid and sphingosine 1-phosphate. Faseb J 12:1589–1598
37.
Fang X, Gaudette D, Furui T, Mao M, Estrella V, Eder A, Pustilnik T, Sasagawa T, Lapushin R, Yu S, Jaffe RB, Wiener JR, Erickson JR, Mills GB (2000) Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer. Ann NY Acad Sci 905:188–208
38.
Fang X, Schummer M, Mao M, Yu S, Tabassam FH, Swaby R, Hasegawa Y, Tanyi JL, LaPushin R, Eder A, Jaffe R, Erickson J, Mills GB (2002) Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta 1582:257–264
39.
Mills GB, Eder A, Fang X, Hasegawa Y, Mao M, Lu Y, Tanyi J, Tabassam FH, Wiener J, Lapushin R, Yu S, Parrott JA, Compton T, Tribley W, Fishman D, Stack MS, Gaudette D, Jaffe R, Furui T, Aoki J, Erickson JR (2002) Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer. Cancer Treat Res 107:259–283
40.
Fishman DA, Liu Y, Ellerbroek SM, Stack MS (2001) Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Res 61:3194–3199
Metadata
Title
Lysophosphatidic acid stimulates fas ligand microvesicle release from ovarian cancer cells
Authors
Yuru Meng
Shijun Kang
David A. Fishman
Publication date
01-08-2005
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 8/2005
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-004-0642-5

Other articles of this Issue 8/2005

Cancer Immunology, Immunotherapy 8/2005 Go to the issue

Original Article

Immuno-gene therapy of melanoma by tumor antigen epitope modified IFN-γ

Original Article

Treatment of stage III–IV nasopharyngeal carcinomas by external beam irradiation and local low doses of IL-2

Original Article

Semi-mature IL-12 secreting dendritic cells present exogenous antigen to trigger cytolytic immune responses

Original Article

Safety evaluation of DT388IL3, a diphtheria toxin/interleukin 3 fusion protein, in the cynomolgus monkey

Review

Tumor antigen-specific T helper cells in cancer immunity and immunotherapy

Original Article

Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits